Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PsyBio Therapeutics Corp V.PSYB.H

Alternate Symbol(s):  PSYBF

PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.


TSXV:PSYB.H - Post by User

Post by partystockeron Dec 29, 2021 4:36pm
242 Views
Post# 34268955

Still awaiting $ORIG ipo date- but that may be a good thing

Still awaiting $ORIG ipo date- but that may be a good thing

As the end of Q4 draws nearer by the hour, it appears we won’t be getting a clear IPO date from Origin therapeutics. However, as the psychedelic market continues to see all-time lows, I don’t think this is a bad thing. 


Seeing as Origin has an incredibly strong portfolio of both publicly and privately held companies, the right IPO date that capitalizes on a swing in the market would give them an amazing opportunity to see some huge growth from IPO price. 


The big thing holding this industry back is public acceptance and regulation. We all know that. I expect that 2022 will prove to be a big year of growth for the industry, in terms of continuing to lay the foundations to springboard off of. I think it’s smart of Origin’s management to hold off on IPO until such groundwork is laid, and the industry is ready to see a solid resurgence and broader investor interest. 


We’ll hopefully see some updated guidance from Origin’s leadership early in Q1 as to what the company’s plans are for going public. As of now, we can expect the company to IPO under the ticker $ORIG in Canadian markets. 


The company has a pretty enticing investor package that is available here. Definitely worth taking a look at IMO. 


https://originpsychedelics.com/investors/?gclid=Cj0KCQiAq7COBhC2ARIsANsPATEmrShLff1iHcZFxWVMiPr7O3nO1k9HyWy8FMjBW-_7q9jxabfa35oaAjzIEALw_wcB
<< Previous
Bullboard Posts
Next >>